This clinical trial is focused on studying the prevention of Mpox infection, which is a disease caused by a virus similar to the one that causes smallpox. The study will use a vaccine called IMVANEX, which is a suspension for injection containing a live virus known as Modified Vaccinia Ankara – Bavarian Nordic Live Virus. This vaccine is designed to help the body build protection against the Mpox virus.

The purpose of the study is to understand how the body’s immune response, specifically the antibodies that fight the virus, changes over time after receiving the vaccine. Participants in the study will receive either one or two doses of the vaccine. The study will monitor the levels of these antibodies at different times, up to 48 weeks after vaccination. This will help researchers learn more about how long the vaccine’s protection lasts and what factors might influence this.

Throughout the study, participants will have regular check-ups to measure the presence of antibodies and to ensure their well-being. The study will also look at the vaccine’s ability to neutralize the virus in laboratory settings and check for any other infections that might occur during the study period. This research aims to provide valuable information on the effectiveness of the IMVANEX vaccine in preventing Mpox infection.